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Abstract The prevalence of non-alcoholic fatty liver
disease (NAFLD) and non-alcoholic steatohepatitis
(NASH) is increasing world-wide in parallel to the increase
of the obesity epidemic. Insulin resistance (IR) and the
accumulation of triglyceride-derived toxic lipid metabo-
lites play a key role in its pathogenesis. Multiple
biomarkers are being evaluated for the non-invasive diag-
nosis of NASH. However, a percutaneous liver biopsy is
still the gold standard method; the minimal diagnostic
criteria include the presence of [5 % macrovesicular
steatosis, inflammation, and liver cell ballooning. Several
pharmaceutical agents have been evaluated for the treat-
ment of NASH; however, no single therapy has been
approved so far. Due to the increasing prevalence and the
health burden, there is a high need to develop therapeutic
strategies for patients with NASH targeting both those with
early-stage disease as well as those with advanced liver
fibrosis. There are unique challenges in the design of
studies for these target populations. Collaborative efforts of
health authorities, medical disease experts, and the phar-
maceutical industry are ongoing to align options for a
registrational pathway. Several companies pursuing dif-
ferent mechanisms of action are nearing the end of phase II
with their candidates. This manuscript reviews those
compounds with a variety of mode of actions that have
been evaluated and/or are currently being tested with the
goal of achieving a NAFLD/NASH indication.
Key Points
Prevalence of steatohepatitis is increasing worldwide.
Patients with obesity, type 2 diabetes (T2DM), and
insulin resistance are specifically affected.
There is no approved drug for the treatment of
NASH but there are a wide variety of compounds
with different modes of actions currently in clinical
development.
The ideal treatment is expected, in the short term, to
reduce liver inflammation and fibrosis, and improve
insulin sensitivity and metabolic complications;
however, in the long term, a benefit in reducing
cardiovascular and hepatic outcomes will need to be
demonstrated.
1 Introduction
Nonalcoholic fatty liver disease (NAFLD) is defined by the
presence of hepatic accumulation of triglycerides in the
hepatocytes in the absence of significant alcohol intake, viral
infection, or any other specific etiology of liver disease. It
represents a histopathologic spectrum ranging from steatosis
alone to nonalcoholic steatohepatitis (NASH), fibrosis, and
cirrhosis. NAFLDmay lead to liver failure or hepatocellular
carcinoma. NASH is currently the most common cause of
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liver disease in the West, but it is important to note that
cardiovascular disease is the single most important cause of
mortality in this patient population [1, 2].
NAFLD is closely associated with obesity and insulin
resistance and its prevalence has risen rapidly in parallel
with the dramatic global rise in levels of obesity and dia-
betes mellitus [3]. It has been suggested that NAFLD
represents the hepatic manifestation of the metabolic syn-
drome [4].
NAFLD is a major potential threat to public health. It
affects at least 30 % of the general population and is pre-
sent in more than 60 % of obese subjects. Patients with a
diagnosis of NAFLD have been shown to have a signifi-
cantly higher risk of diabetes, cardiovascular disease, and
overall and liver-related mortality when compared with an
age- and sex-matched general population [2]. Cirrhosis due
to NASH is now the third most common cause of liver
transplantation in the USA [5].
There are many uncertainties in the diagnostic approa-
ches, evaluation, and management of NASH. The formal
diagnosis still requires a liver biopsy, a procedure that is
invasive, somewhat painful, and may be associated with
life-threatening complications due to the potential for
trauma and bleeding complications that occur in some
individuals. Additionally, it has several limitations as a
surrogate marker of clinical outcomes. For instance, it
enables an evaluation of only a small sample of the liver
parenchyma, which may not be representative of the
pathology in the rest of the liver tissue [6]. Due to these
limitations, the high cost, and the lack of effective treat-
ment options, only a minority (less than 25 %) of academic
gastroenterologists and hepatologists in the USA routinely
perform liver biopsies in patients with presumed NASH
[7].The lack of accurate, reproducible, and easily applied
methods has been a major limitation not only in the clinical
management of NASH patients but also for research.
Although several drugs with different targets have
shown efficacy in clinical trials of various designs, there
are currently no approved therapies for NASH. A major
impediment to therapeutic advances to improve outcomes
in NAFLD and NASH is the long natural history of the
disease (i.e., it can take decades for NAFLD to progress to
NASH, and subsequently for NASH to become symp-
tomatic and to potentially lead to cirrhosis and death).
Therefore, the critical need guiding drug development for
NAFLD/NASH is to identify viable surrogates that are
predictive of those outcomes. There are ongoing efforts
among members of the scientific community, global reg-
ulatory agencies, and the pharmaceutical industry to agree
on the best path forward to determine and validate the
appropriate markers for NASH diagnosis that can be used
to evaluate efficacious and safe therapies to treat patients
with NASH.
The objective of this review is to summarize the mag-
nitude of the health burden and the current state of
NAFLD/NASH diagnosis, to discuss the available data for
several compounds that have completed clinical trials in
NAFLD/NASH (including those currently in clinical
development aiming for a NAFLD/NASH indication), and
to discuss the challenges and potential future paths for
development.
2 Prevalence and Natural History
Excess liver fat is now extremely common, consistent with
the increasing prevalence of the metabolic syndrome linked
to the global epidemic of obesity. It has been estimated that
more than 30 % of adults in the USA and other Western
countries have NAFLD [8].
The reported prevalence of NAFLD varies depending on
the methodology used and the population studied. Most of
the studies in the general population are based on liver
ultrasound (US) or liver enzymes, with liver biopsy mostly
restricted to subjects at high risk and magnetic resonance
imaging (MRI) and spectroscopy (MRS), typically only
used in clinical research settings.
Population-based studies in the USA estimate that the
prevalence of NAFLD ranges between 17 and 46 % in the
general population [9]. In the Dallas Heart Study [10],
when assessed by MRS, the prevalence of NAFLD was
31 %. Most recently, the prevalence of NAFLD was 46 %
in a multi-ethnic group of patients based on ultrasonogra-
phy. Interestingly, NASH was confirmed in a subset of
12.2 % of this total cohort [11].
The prevalence can be higher in certain populations.
There is a very high prevalence of NAFLD in obese sub-
jects and among patients with T2DM. In patients with
severe obesity undergoing bariatric surgery, the prevalence
of NAFLD can exceed 90 % [12]. The prevalence of
NAFLD in patients with T2DM has been estimated to be
between 60 and 70 % [9]. In addition, T2DM worsens liver
disease, although the underlying mechanisms remain
unclear [13]. Several studies have reported that the pres-
ence of T2DM is associated with a two- to four-fold
increase in serious liver disease, cirrhosis, and hepatocel-
lular carcinoma [14].
High serum triglyceride levels and low serum HDL
levels are also very common in patients with NAFLD. The
prevalence of NAFLD in individuals with dyslipidemia
attending lipid clinics was estimated to be 50 % [15].
Ethnic variation has also been suggested to influence the
phenotype of patients with NAFLD. It has been suggested
that Hispanics (predominantly of Mexican origin) are at
particular risk for NAFLD and tend to have a more
aggressive disease course [16]. However, Kallwitz et al.
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[17] found no significant differences in hepatic steatosis,
NASH, or liver fibrosis (CF2) between morbidly obese
Hispanic and non-Hispanic White patients receiving bar-
iatric surgery. It has been reported that when Hispanics and
Caucasians are matched for adiposity, the severity of
NASH is similar [18], suggesting that ethnic differences
might be a reflection of the differences in metabolic risk of
Hispanics in these studies.
NAFLD has also recently been recognized among chil-
dren. In the USA, the prevalence of elevated plasma
aminotransferase levels in adolescents was reported
between 3.5 and 12.4 %, higher in males relative to
females and the highest among Mexican American boys
[19]. This likely underestimates the true prevalence of
NAFLD in children, as many patients with NAFLD have
normal liver enzymes.
The natural history of progression from NAFLD to
NASH remains unclear. While most patients with simple
hepatic steatosis are likely to have a benign and non-pro-
gressive course, about 12–40 % of patients with fatty liver
will progress to NASH. Approximately 15–20 % of
patients with NASH will subsequently develop liver
fibrosis and cirrhosis. It has also been reported that a fair
proportion of patients may progress from liver steatosis to
advanced fibrosis [20, 21]. NAFLD patients with progres-
sive fibrosis have been reported to be more insulin resistant
and significantly more likely to have a weight gain
exceeding 5 kg [21]. Patients with NASH are also at
increased risk of hepatocellular carcinoma, even in the
absence of cirrhosis [22], with an approximately threefold
increase in liver-related mortality [23]. In a 33-year follow-
up study, fibrosis stage was found to be the strongest pre-
dictor for disease-specific mortality [24]. Patients with
NAFLD and type 2 diabetes are especially at risk for
mortality due to hepatic complications [23]. However,
most patients with NAFLD will not have a progressive
disease and some patients can spontaneously improve.
Among 359 individuals in the NASH clinical research
network (CRN) database with two or more biopsies sepa-
rated by a mean of 4.4 years, 128 cases showed fibrotic
progression and 103 showed regression [25]. This bidi-
rectional nature of the disease adds difficulty in the inter-
pretation of data in clinical trials. The challenge remains in
the early identification of those individuals that will pro-
gress to NASH and cirrhosis.
3 Pathogenesis
Insulin resistance (IR) plays a major role in the patho-
genesis of NAFLD and is considered a key factor in the
initiation and perpetuation of NASH [26, 27]. A ‘‘two-hit’’
process has been proposed [28]. The first ‘‘hit’’ involves
accumulation of triglycerides in the hepatocytes, which is
closely associated with central obesity and insulin resis-
tance. IR leads to enhanced lipolysis which in turn
increases circulating free fatty acids and their uptake by the
liver. An increased delivery of free fatty acids to the liver is
combined with impaired hepatic fatty acid metabolism. On
the other hand, the accumulation of lipid molecules in the
liver exacerbates insulin resistance by interfering with the
tyrosine phosphorylation and signalling potential of cellu-
lar insulin receptor substrates.
The factors involved in determining the progression
from steatosis to steatohepatitis and fibrosis are less well
understood. The accumulation of fat in the liver appears to
have several cellular and metabolic effects, including:
upregulation of hepatocyte apoptosis, mitochondrial dys-
function with increase in reactive oxygen species (ROS)
that leads to lipid peroxidation of cell membranes, and
induction of pro-inflammatory genes such as TNFa (tumor
necrosis factor alpha) and COX-2 (cyclooxygenase-2),
which also induce additional inflammatory mediators with
pro-fibrotic effects. On the other hand, the increased
secretion of adipocytokines (leptin, resistin) and pro-in-
flammatory markers (TNFa) from the adipose tissue in the
setting of insulin resistance, and the decreased levels of
anti-inflammatory cytokines such as adiponectin, also
produced by adipocytes, facilitates a net balance that leads
to apoptosis, necroinflammation, and fibrosis in the hepa-
tocytes [29]. Lipid released from damaged hepatocytes
may also result in mechanical and/or inflammatory cell-
mediated occlusion of hepatic venules, leading to
parenchymal collapse and fibrosis [30]. Immune responses
to lipid peroxidation products may also be involved in the
disease progression [3]. There is also an activation of
profibrogenic cytokines, such as interleukin-10 and trans-
forming growth factor-b, which in turn are regulated by
other factors including leptin and neurotransmitters such as
noradrenaline.
4 Diagnosis and Current Status of Non-Invasive
Methods
The diagnosis of NAFLD requires a demonstration of
excess liver fat by imaging or histology with exclusion of:
(1) significant alcohol consumption, (2) competing etiolo-
gies for hepatic steatosis (e.g., hepatitis C, medications,
parenteral nutrition, Wilson’s disease, severe malnutrition,
lipodystrophy, etc.), and (3) coexisting causes for chronic
liver disease (e.g., hemochromatosis, autoimmune liver
disease, chronic viral hepatitis). Although alcoholic liver
disease and NAFLD have similar pathological spectra,
from simple hepatic steatosis to steatohepatitis and liver
cirrhosis, the clinical characteristics of these two diseases
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differ [31]. Unfortunately, self-report questionnaires often
underestimate patients’ actual alcohol consumption. Sev-
eral recently developed biochemical measures (e.g., ethyl
glucuronide, ethyl sulfate, phosphatidyl ethanol, and car-
bohydrate-deficient transferrin) can provide additional
information on a patient’s use of alcohol [32].
NAFLD is frequently underdiagnosed, as most of the
time it is asymptomatic and patients usually have normal
liver aminotransferases [33, 34]; thus, clinicians often do
not suspect the potential presence of NAFLD. Liver biopsy
is still the gold standard method for the diagnosis, grading
(severity of ongoing injury) and staging (degree of pro-
gression to cirrhosis) of the disease [35]. The minimal
criteria for the diagnosis of steatohepatitis include the
presence of[5 % macrovesicular steatosis, inflammation,
and liver cell ballooning, typically with a predominantly
centrilobular distribution in adults. The staging and grading
of liver disease was a concept introduced in the mid-1990s.
This early proposed grading scheme for steatohepatitis
(mild, moderate, or marked) was a composite of four
separate features: steatosis, ballooning injury, lobular
inflammation, and portal inflammation [36]. More recently,
the pathologists in the NASH clinical research network
validated an updated scoring system that can be used to
assess histologic change in studies of both adults and
children with NAFLD/NASH (Table 1) [37]. The NAFLD
activity score (NAS) is an un-weighted composite of
steatosis, inflammation, and ballooning scores. It is a useful
tool to quantify disease activity and assess changes in
clinical trials. However, the diagnosis of NASH is defined
by the presence and pattern of specific histologic abnor-
malities and the NAS has not been validated as a marker
for likelihood of disease progression (e.g., cirrhosis, mor-
tality) and/or response to therapy. A score of 5 or more is
associated with a greater likelihood of having NASH.
However, a NAS C5 does not confirm NASH. For instance,
in an evaluation of 976 liver biopsies with a NAS C5 of
976 adults in the NASH clinical research network (CRN)
database, 86 % had NASH and 3 % did not have steato-
hepatitis (SH). Only 75 % of biopsies with definite SH had
a NAS C5, whereas 28 % of borderline SH and 7 % of
‘‘not SH’’ biopsies had NAS C5 [38]. The use of NAS is
currently limited to clinical trial settings. Clinically
important differences have been reported between com-
munity general pathologists and expert hepatologists in
assessing NAFLD using the NASH CRN scoring system,
and more studies are needed to investigate its suitability for
community-based clinical practice [39].
One of the most pressing challenges in this field is the
lack of a validated, non-invasive set of tests to diagnose
NASH, and liver fibrosis in patients with NASH. Sensi-
tivity and specificity of some of these tests to identify
NASH patients are described in Table 2.
Mild elevations of alanine aminotransferase (ALT) and
aspartate aminotransferase (AST), usually in the range of
1.5- to threefold above the upper limit of normal, in the
absence of other diagnoses strongly suggests NASH.
However, it is also essential to note that approximately
two-thirds of patients have normal aminotransferase levels
at any given time [6], grade, and stage of their disease. Use
Table 1 Non-alcoholic steatohepatitis (NASH) clinical research network (CRN) scoring system describes the non-alcoholic fatty liver disease
activity score (NAS) and the fibrosis score (disease stage). The NAS represents the sum of scores for steatosis, lobular inflammation, and
ballooning, and ranges from 0 to 8. The total score for the fibrosis stage (below) ranges from 0 to 4
Steatosis Lobular inflammation Ballooning Total
Degree Description (% hepatocytes) Degree Description Degree Description
0 \5 0 0/209a 0 0
1 5–33 1 \2 foci/2009 1 Few/inapparent
2 34–66 2 2–4 foci/2009 2 Easily noted/many
3 [67 3 [4 foci/2009
NAS score 0–3 0–3 0–2 0–8
Stage Fibrosis location
1A Zone 3, perisinusoidal, delicate
1B Zone 3, perisinusoidal, dense
1C Portal, periportal only
2 Zone 3, perisinusoidal ? portal, periportal only
3 Bridging fibrosis
4 Cirrhosis
a Optical field
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of the recently proposed modified normal ALT thresholds
has provided improved sensitivity to identify patients who
are ‘‘at risk’’ for chronic liver disease with an acceptable
trade-off in specificity [40]. However, simply documenting
elevations in liver enzymes is still unreliable for the
diagnosis and monitoring of the disease activity.
Table 2 Accuracy of some biomarkers and diagnostic panels for non-alcoholic steatohepatitis (NASH) (inflammation, oxidative stress, apop-
tosis) and advanced liver fibrosis (bottom). A wide range of biomarkers and panels have been tested. In general, studies are small and need
further validation. The sensitivity, specificity, and area under the receiver operating characteristic (AUROC) curves vary depending on the
defined cut-off point
Test AUROC (%) Cut-off
value
Sensitivity
(%)
Specificity
(%)
PPV NPV
TNFa mRNA [117] 0.685 100 ng/mL 66.7 74.1
IL-6 [118] 0.817 4.6 pg/mL 58.1 100
hsCRP [119] 0.906 3.5 82 88
Ferritin [120] 0.82
0.732
240 ng/mL
196
91
64.2
70
76.5
Adiponectin [121] 0 .765 \4 lg/mL 68 79
CK-18 0.93 [122] 395 U/L 85.7 99
0.83a [45] 225 U/L 70 82 84 73
250 U/L 60 93 95 69
300 U/L 53 100 100 67
0.84b [68] 121–479 78 87
95 % CI 64–92
Hyaluronic acid [123, 124] 0.797 43 ng/mL 97.1
NAFLD diagnostic panel (diabetes,
gender, BMI, TG, CK-18) [47]
0.81
0.85
0.221
0.3641
0.6183
B1.455c
[0.676d
91.2
79.4
44.1
90
67
47.4
73.7
92.1
60
97
60.8
73
83.3
85.7
80
64.8
Hyaluronic acid [125] 0.975 148.8 ng/mL 97.5 95.7
FIB4 index (age, ALT, AST, platelet count) [125, 126] 0.802 \1.30 74 71 43 90
ELF (HA, TIMP1, PIIINP) [51, 68] 0.90
0.76e
0.82f
0.90g
0.3576
-0.2070
-0.1068
0.3576
80
61
70
80
90
80
80
90
71 94
Fibrotest (a2macroglobuline, haptoglobin,
GGT, tot BB, ApoA1) [127]
0.81 0.3
0.7
77
15
77
98
54
73
90
76
NAFLD fibrosis score (age, hyperglycemia,
BMI, platelet count, albumin, AAR) [9, 16, 68]
0.84
0.85h
95 % CI 0.81–0.90
B1.455
[0.676
B1.455
[0.676
82
51
90 (86–95)
64 (59–70)
77
98
60 (56–65)
97 (94–99)
56
90
93
85
PPV positive predictive value, PNV negative predictive value, CK-18 cytokeratin 18, BMI body mass index, TG fasting triglycerides, ALT alanine
aminotransferase, AST aspartate aminotransferase, ELF enhanced liver fibrosis panel, HA hyaluronic acid, TIMP1 tissue inhibitor of metallo-
proteinase 1, PIIINP amino-terminal propeptide of type III collagen, AAR AST/ALT ratio
a Accuracy for differentiating patients with NASH from those with simple steatosis with three different cut points: 225, 250, and 300 U/L. For
every 50-U/L increase in the plasma level of CK-18, the likelihood of having NASH increased 30 % [OR (95 % CI) 1.3 (1.1–1.4)]. CK-18
fragment levels were significantly higher in patients with fibrosis as compared to those without fibrosis [45]
b Summary estimates of nine studies [68]
c To exclude advanced fibrosis
d To identify the presence of advanced fibrosis
e 95 % CI 0.69–0.83 to identify any fibrosis (stage 1–4)
f 95 % CI 0.75–0.88 to identify CF2
g 95 % CI 0.84–0.96 to identify CF3
h Summary estimates of 13 studies. To identify CF3
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The presence of the metabolic syndrome is a strong
predictor of steatohepatitis in patients with NAFLD [41]. In
fact, a confirmed diagnosis of the metabolic syndrome has
been suggested to be used to best identify patients with
persistently abnormal liver biochemistries who would
benefit diagnostically and prognostically from a liver
biopsy [41].
Markers of inflammation like TNFa, interleukin-6, high-
sensitivity C-reactive protein, monocyte chemoattractant
protein-1, pentraxin 3, and ferritin, among others, have
been reported to be elevated in patients with NASH.
However, most of these studies were small and did not
provide a cut-off value. Their potential for differentiating a
diagnosis of NASH from fatty liver has not been fully
elucidated [42, 43].
Oxidative stress has been recognized as an important
mechanism in the pathogenesis of NASH. However, cir-
culating markers known to be associated with a variety of
oxidation pathways were investigated for use in NASH
diagnosis, but they failed to show robust and consistent
results. One possible explanation for these findings is that
the serum or plasma measurement of oxidative markers
may not necessarily reflect the activity of different oxida-
tion pathways in the liver [42, 43].
Currently, the most promising biomarker in the circu-
lation for the diagnosis of NASH is represented by serum
cytokeratin-18 (CK-18) levels, which is associated with the
degree of hepatocyte apoptosis. Circulating levels of CK-
18 fragments have been investigated extensively for the
presence of steatohepatitis in patients with NAFLD. Sen-
sitivity and specificity values have varied across studies
depending on the diagnostic ‘‘cut-off level’’ used. CK-18
fragments have been reported to be significantly lower for
NAFL than for biopsy-proven borderline or definite NASH
[44]. However, there is considerable variability in the
suggested cut-offs and their respective diagnostic accuracy
among studies [45]. A few studies suggested that CK-18
fragments may have a better performance for the diagnosis
of NASH when combined with other tests (e.g., liver
attenuation on computed tomography (CT) scan, fibroblast
growth factor 21, etc.) [43].
Several other biomarkers have been evaluated in
NAFLD/NASH populations: serum adiponectin is lower in
patients with NASH than in those with simple steatosis.
Soluble FAS (sFAS) is a death receptor from the TNF
receptor family that has been implicated in apoptosis and is
upregulated in NASH in animal models. An apoptosis
panel combining CK-18 with sFAS was found to have
greater accuracy than either alone [46].
Different algorithms have been proposed for the recog-
nition of NASH using non-invasive techniques (Table 2).
Many of these include components of the metabolic syn-
drome in their formula. For instance, the NAFLD diagnostic
panel includes bodymass index (BMI), fasting triglycerides,
gender, the presence of diabetes, and CK-18 [47].
A non-invasive and cost-effective marker of hepatic
fibrosis would be extremely valuable to detect NASH
patients that may progress to cirrhosis (Table 2). Current
non-invasive methods for assessing fibrosis range from
serum biomarker assays to advanced imaging techniques.
One of the biggest challenges to developing non-invasive
tests is the lack of a reliable gold standard, since even the
percutaneous liver biopsy has a poor diagnostic perfor-
mance. In a study using a blinded evaluation of two cores
of liver sampled at the same biopsy session, only about half
of the time the cores were assessed as having the same
stage of fibrosis. Additionally, potential regional variability
may cause meaningful sampling variability [48]. This
variability compromises the ability of the liver biopsy to
serve as a reliable gold standard to which the non-invasive
tests and biomarkers are compared.
Several non-invasive methods have been evaluated as
predictors of advanced fibrosis in patients with NAFLD.
Constituents of the extracellular matrix [hyaluronic acid
(HA), tissue inhibitors of metalloproteinase-1(TIMP-1),
procollagen type III N-terminal peptide (PIIINP), type IV
collagen 7S] domain seem to have ‘‘acceptable’’ (Table 2)
sensitivity and specificity for the detection of NASH
although not without controversion. Several diagnostic
panels have been developed for the prediction of significant
fibrosis. The NAFLD fibrosis score was developed from a
large cohort (n = 773) and is calculated from six variables:
age, hyperglycemia, BMI, platelet count, albumin, and AST/
ALT ratio [49]. The ‘‘BAAT’’ scoring system [50] is cal-
culated based on the following parameters: age, BMI,
triglycerides, and ALT. The ELF panel consists of plasma
levels of three matrix turnover proteins (HA, TIMP-1, and
PIIINP). The liver fibrosis panel adds the age to these three
serum biomarkers [51]. Different cut-off values have been
proposed. In general, the higher the cut-off value, the higher
the specificity, but at the expense of losing sensitivity.
4.1 Imaging
Liver US is currently the imaging technique of choice in
clinical practice for the diagnosis of NAFLD, given its
wide availability and relatively low cost. Compared with
ultrasonography, however, CT scanning, MRI, and MRS,
all have a better sensitivity and specificity in detecting fatty
liver. Both MRS and MRI have been proven to accurately
measure hepatic fat in both adults and children, and are
increasingly being used in clinical research [52, 53].
Hepatic fat content[5.5 % is consistent with the diagnosis
of hepatic steatosis [10].
Tests that employ measurement of stiffness as a bio-
marker of hepatic fibrosis include magnetic resonance
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elastography [54] and US-based transient elastography [55].
The rationale for these studies is that the collagen deposition
associated with fibrosis produces a lattice-like framework
that imparts rigidity to the pressure compliance of the liver.
Transient elastography (TE) has been validated as a measure
of fibrosis across a wide spectrum of chronic liver disease
(hepatitis B and hepatitis C) and has overall a good accuracy.
It has the advantage of being quick, easy to learn, and well
tolerated by patients [55]. The new XL probes provide
comparable diagnostic accuracy to the standard probe and
enable the examination of obese patients [56] A detailed
description of all these available methods is beyond the
scope of this article and can be found elsewhere [56–58].
In patients with advanced liver disease, hepatic venous
pressure gradient (HVPG) assessment is the best-validated
predictor of eventual decompensation [57]. It provides an
indirect measure of portal venous pressure [58]. HVPG has
been shown to correlate with different outcomes [59, 60]
and has been proposed as a potential surrogate endpoint
that might be considered reasonably likely to predict
clinical outcome to support an accelerated approval [61].
For instance, in patients with cirrhosis but no varices (all
with an HVPG[5 mmHg), HVPG has been shown to be
the best predictor of the development of varices. Inversely,
in patients with compensated cirrhosis (without varices), a
decrease in HVPG[10 % is associated with a significantly
lower incidence of varices. In a study performed in post-
transplant hepatitis C patients treated with antiviral ther-
apy, HVPG decreased significantly in those who had an
improvement in fibrosis stage, remained stable in those in
whom fibrosis remained stable, and worsened in those in
whom fibrosis progressed. Since the HVPG test is invasive
and requires skilled practitioners, it is not widely used.
5 Available Treatment Options and Drugs
in Development Pipelines
Currently, there is no approved therapy for NAFLD/
NASH. Treatment strategies may be grouped into those
that address weight loss, improve insulin sensitivity and/or
are antidiabetics, reduce lipids, are antioxidants, or target
the liver.
5.1 Weight Loss
5.1.1 Lifestyle Intervention
Lifestyle modification is the first step for the treatment of
the metabolic comorbidities in NAFLD and, at present, it is
the standard of care to treat NAFLD itself. Many studies
indicate that lifestyle modification may reduce amino-
transferases and improve hepatic steatosis when measured
by either US [62, 63] or MRI and MRS [64, 65]. In the
LOOK AHEAD trial, a 12-month, randomized controlled
trial investigating the long-term health impact of an
intensive lifestyle intervention (ILI) in overweight or obese
adults with type 2 diabetes, a total of 96 subjects completed
an MRS substudy to quantify hepatic steatosis (Fatty Liver
Ancillary Study). After 12 months, the participants
assigned to ILI (n = 46) lost more weight (-8.5 vs. -
0.05 %; p\ 0.01) and had a greater decline in steatosis
than those assigned to the standard diet arm (SDA) (-50.8
vs. -22.8 %; p\ 0.04). At 12 months, 26 % of SDA
participants and 3 % (one of 31) of ILI participants without
NAFLD at baseline developed NAFLD (p\ 0.05) [66].
Several studies using a variety of interventions, either by
diet alone or in combination with different exercise pre-
scriptions [64, 67], have consistently reported a significant
reduction in liver fat by an average of *40 % (ranging
from 20 to 80 %). In general, the degree of hepatic fat
reduction was proportional to the intensity of the lifestyle
intervention [68]. Loss of at least 3–5 % of body weight
appears necessary to improve steatosis, but a greater weight
loss (up to 10 %) seems to be needed to improve
necroinflammation [41].
5.1.2 Antiobesity Drugs
A few small studies suggest that weight loss induced by
medications such as orlistat [69], sibutramine [70], or
cannabinoid-1 (CB1) antagonists [71] may lead to an
improvement in steatosis and reduction in ALT levels.
However, there is very little evidence from controlled clinical
trials to support the hypothesis that either orlistat or sibu-
tramine improve NAFLD in the short term and there are
currently no long-term data available regarding the effect of
these medications on liver-related outcomes. The endo-
cannabinoid system has emerged as a pivotal mediator of
acute and chronic liver injury. Unfortunately, the CB1
antagonist rimonabant, initially approved for themanagement
of overweight and related cardiometabolic risks, was with-
drawn because of an alarming rate of adverse effects affecting
mood. Attempts to avoid potential psychiatric adverse effects
of drugs in this class has prompted the development of
peripherally-restricted CB1 antagonists with limited brain
penetrance. The efficacy of several of these compounds has
been validated in preclinical models of NAFLD where bene-
ficial effects on fibrosis have been observed [72].
5.1.3 Bariatric Surgery
Data suggest that most obese patients undergoing bariatric
surgery have NAFLD [73]. A recent review of 15 studies of
766 paired liver biopsies in patients undergoing bariatric
surgery reported that steatosis resolved in 91.6 % (95 % CI
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82.4–97.5), steatohepatitis improved in 81.3 % (95 % CI
61.9–94.9), and fibrosis in 65.5 % (95 % CI 38.2–88.1) of
cases [68]. In a 5-year prospective study of bariatric sur-
gery in 381 subjects, steatosis, ballooning, and NAS
improved significantly, NASH resolved in 48 % of cases.
However, fibrosis worsened slightly but significantly. Most
of the improvement occurred within 1 year, and, interest-
ingly, it was the persistence of insulin resistance at 1 year,
rather than the degree of weight loss, that predicted the lack
of a histologic response at 5 years [74].
Though some evidence suggest that steatosis, steato-
hepatitis, and fibrosis may significantly improve or even
completely resolve after bariatric surgery, a Cochrane
review concluded that the lack of randomized clinical trials
prevents a definitive assessment of the benefits and harms
of bariatric surgery as a therapeutic approach for patients
with NASH [75].
5.2 Insulin-Sensitizing Agents
5.2.1 Thiazolidinediones
Given the role of insulin resistance in the pathogenesis of
NASH, insulin sensitizers such as PPAR-gamma agonists
have been extensively tested. Several pilot studies exam-
ining the effect of glitazones on NAFLD and NASH have
reported favorable results, with improvement in both liver
function tests and liver histology [76–78]. Rosiglitazone
has been proven to improve serum aminotransferase levels
and hepatic steatosis, but not inflammation or fibrosis [79].
In a phase II, double-blind, placebo-controlled, 24-month
study, pioglitazone significantly improved aminotrans-
ferase levels, steatosis, ballooning, and inflammation in
patients with NASH who had impaired glucose tolerance or
T2DM. The NAS improved with pioglitazone in 73 %
compared with 24 % of placebo-treated patients
(p\ 0.001) and there was a trend toward improvement in
fibrosis [76]. The PIVENS [78] (pioglitazone vs. vitamin E
vs. placebo for the treatment of non-diabetic patients with
non-alcoholic steatohepatitis) study was a large multicen-
ter, randomized, 96-week clinical trial that randomized 247
non-diabetic patients with biopsy-confirmed NASH to
pioglitazone (30 mg/day), vitamin E (800 IU/day), or pla-
cebo for 24 months. The primary endpoint was an
improvement in the composite of NAS C2 points with at
least a 1-point improvement in hepatocellular ballooning
and a 1-point improvement in either the lobular inflam-
mation or steatosis score, and no increase in the fibrosis
score. This was achieved in 19 % of subjects in the placebo
group compared with 34 % in the pioglitazone group
(p = 0.04, NS) (pre-specified alpha of 0.025). In the vita-
min E group, 43 % of the patients had improvements in
NASH as defined by the primary endpoint (p\ 0.01).
Although pioglitazone did not meet the pre-specified sig-
nificance level for the primary outcome, it was associated
with highly significant reductions in the individual vari-
ables of steatosis, inflammation, and hepatocellular bal-
looning, as well as with improvements in insulin resistance
and liver-enzyme levels. It also led to the resolution of
steatohepatitis in a significant proportion of subjects. One
possible reason for the failure to achieve the primary out-
come with pioglitazone therapy is that more subjects in the
pioglitazone group than in the vitamin E and placebo
groups were classified as not having had ballooning at
baseline (a reduction in ballooning was one of the criteria
for the primary outcome and thus these subjects were
classified as non-responders). Additionally, more subjects
in the pioglitazone group did not have a post-treatment
liver biopsy (therefore considered by default as non-re-
sponders). Patients in the vitamin E group did achieve a
significant improvement in SH as defined by the primary
endpoint. When vitamin E and pioglitazone patients were
matched for baseline histology (i.e., ballooning), no sta-
tistical differences between both treatments were observed.
The Practice Guideline by the American Association for
the Study of Liver Diseases, American College of Gas-
troenterology, and the American Gastroenterological
Association [80] suggest that pioglitazone can be used to
treat steatohepatitis in non-diabetic patients with biopsy-
proven NASH. However, pioglitazone is not approved for
the treatment of NASH, data in diabetics is scarce, and
long-term safety and efficacy of pioglitazone in patients
with NASH has not been established.
5.2.2 Metformin
Several studies have investigated the effect of metformin
on aminotransferases and liver histology in patients with
NASH. Although some small, open-label studies suggested
that metformin reduced insulin resistance and aminotrans-
ferases, a randomized control trial of metformin versus
placebo with similar dietary and exercise interventions in
both groups failed to show major benefit for metformin on
hepatic insulin sensitivity, aminotransferases, or liver his-
tology. Metformin is thus not recommended as a specific
treatment for liver disease in adults with NASH primarily
because it has no significant effect on liver histology [80].
5.2.3 Incretin Mimetics
Long-term exenatide administration has been associated
with decreased liver triglyceride content in obese mouse
models [81, 82]. In an open-label, uncontrolled clinical
trial using exenatide to assess drug safety in patients with
diabetes, patients were noted to have had improved AST
and insulin sensitivity over the 3.5-year follow-up period
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[83]. In addition, those with elevated ALT at baseline had a
significant reduction in ALT, and 41 % experienced a
normalization of ALT levels with treatment, independent
of weight loss. In a 12-month prospective study in patients
with type 2 diabetes, both pioglitazone and the combina-
tion of pioglitazone and exenatide [85] led to significant
reductions in liver fat and ALT, but the combination
therapy was superior (-60 %) compared to pioglitazone
alone (-40 %). Importantly, no significant change in
weight was observed in the combination group, suggesting
that there could be a direct effect of exenatide on liver
steatosis independent of metabolic improvements that may
have resulted from weight loss.
From animal data, benefits are not limited to GLP-1R
agonists, which are given at pharmacologic doses, but also
in models with DPP4 deficiency or inhibition. Adminis-
tration of sitagliptin to mice on a linoleic acid and sucrose
diet decreases liver triglycerides and the histologic grade of
hepatic steatosis [86]. In a recently published study, a
4-month treatment with sitagliptin in 30 patients with
T2DM and US diagnoses NAFLD resulted in significant
decreases in AST, ALT, and gamma-GTP levels [87].
However, the potential benefits of dipeptidyl peptidase IV
(DPP-IV) inhibitors on NASH are still preliminary and
long-term randomized clinical trials are warranted.
5.3 Compounds that Reduce Lipids
5.3.1 Statins
The antioxidant and anti-inflammatory properties, the fre-
quent coexistence of NAFLD and dyslipidemia, and the
increased cardiovascular risk of these patients make statins
an attractive therapeutic tool in NAFLD. Strong data support
the use of statins to reduce cardiovascular disease in patients
with dyslipidemia [88]. Though there is reluctance to use
statins in patients with suspected or established chronic liver
disease, including NAFLD and NASH, there is no evidence
that patients with NAFLD and NASH are at higher risk for
serious liver injury from statins than those without liver
disease [41]. However, data on statin efficacy in NAFLD are
sparse. In a pilot trial in which 16 participants with biopsy-
proven NASH were randomized to receive simvastatin
40 mg or placebo for 12 months, no statistically significant
improvement in the aminotransferase level was seen in the
simvastatin group compared with the placebo group. Liver
histology was not significantly affected by simvastatin [89].
In a post-hoc analysis of the Greek Atorvastatin and Cor-
onary Heart Disease Evaluation (GREACE) cardiovascular
outcomes study, statins significantly improved liver bio-
chemistries and cardiovascular outcomes in patients with
elevated liver enzymes likely due to NAFLD [90].
Given the lack of evidence to show that patients with
NAFLD and NASH are at increased risk for serious drug-
induced liver injury from statins, they can be used to treat
dyslipidemia in this patient population [41]. However, until
randomized clinical trials with histologic endpoints prove
their efficacy, statins should not be used to specifically treat
NASH [41].
5.3.2 Omega-3 Fatty Acids
Omega-3 fatty acids have several potential mechanisms of
action leading to hypothesize a potential beneficial effect in
patients with NAFLD. The most important one is the
alteration in the hepatic gene expression, thereby switching
intracellular metabolism from lipogenesis and storage to
fatty acid oxidation and catabolism. There is also evidence
that they improve insulin sensitivity, are anti-inflammatory,
and reduce TNFa levels, thus offering several potential
therapeutic mechanisms.
Animal studies have shown a reduction in hepatic
steatosis, improved insulin sensitivity, and reduced
inflammation and oxidative stress. In humans, preliminary
clinical trials have confirmed this potential, reporting a
reduction in hepatic steatosis on imaging, increased insulin
sensitivity, and improved serum liver function tests [91].
However, most of these trials have been open label. Data
from a randomized, double-blind, 12-month clinical trial
with a pure eicosapentanoic acid compound (Epadel, EPA-
E) in subjects with biopsy-confirmed NASH (NAS C4,
with minimum scores of 1 for steatosis and inflammation,
along with either ballooning or at least stage 1a fibrosis)
have recently been published [92]. Subjects were randomly
assigned to placebo, low-dose EPA-E (1800 mg/day), or
high-dose EPA-E (2700 mg/day). The primary efficacy
endpoint was achieving a NAS\3, without worsening of
fibrosis, or a decrease in NAS by C2 with a contribution
from more than one parameter, without worsening of
fibrosis, after 1 year of the last dose of EPA-E. Epadel did
not demonstrate any improvement of any of the histologic
features of NASH. One potential explanation for the neg-
ative results of this trial is that the dosage of EPA-E was
not high enough for the enrolled USA population. The
dosing for this trial was selected on the basis of existing
data for its efficacy for dyslipidemia in a Japanese popu-
lation. Supporting this hypothesis is the fact that the
observed effect on serum triglycerides in this trial seemed
to be less than what has been seen in Japan. Additionally,
the placebo response rate in this trial was higher than that
reported previously in other studies. Randomized studies to
demonstrate if other omega-3 fatty acids (e.g., docosa-
hexaenoic acid, DHA) are efficacious in improving features
of NASH are warranted.
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5.4 Antioxidation
5.4.1 Vitamin E
Oxidative stress is considered to be a key mechanism in the
second hit leading to hepatocellular injury and disease pro-
gression. Vitamin E has antioxidant properties and has been
investigated as a potential treatment for NASH. Early small
studies of vitamin E for short duration in patients with
NAFLD/NASH reported inconsistent results [93, 94]. How-
ever, in PIVENS [78], a significant difference in the response
to the primary histologic endpoint (an improvement of[2
points in the NAS, with at least 1 point improvement in hep-
atocellular ballooning and 1 point in either the lobular
inflammation or steatosis score, with no worsening of fibrosis)
was observed in patients receiving vitamin E compared with
placebo-treated patients (43 vs. 19 %; p = 0.001). However,
some data suggest potential safety concernswith the long-term
use of vitamin E. Ameta-analysis from 11 trials that tested the
effect of vitamin E supplementation in humans reported that
high-dose vitamin E supplementation (4400 U/day) was
associated with an increase in all-cause mortality [95].
In children with NAFLD, neither vitamin E nor met-
formin was superior to placebo in attaining the primary
outcome of sustained reduction in ALT level in the TONIC
study [96]. However, children treated with vitamin E (who
had biopsy-proven NASH or borderline NASH) had sig-
nificant improvements in secondary histologic outcomes
with vitamin E. Those children who showed an improve-
ment over placebo were those who had hepatocellular
ballooning degeneration on their initial biopsies.
In summary, lifestyle intervention remains the cornerstone
of treatment in NAFLD. However, it is well recognized that
lifestyle changes in diet and exercise are difficult to achieve
and maintain in the long term. Guidelines recommend that
pioglitazone and vitamin E can be used to treat steatohepatitis
in non-diabetic patients with biopsy-proven NASH in a spite
of inconclusive data about their long-term safety [41]. Nev-
ertheless, none of these therapies have been approved for the
improvement ofNASH features in these patients and there is a
huge unmet medical need to get an FDA/EMA approved
therapy for this disease. Ongoing clinical trials may expand
our current understanding of the disease and provide hope for
finding safer and more effective agents in the future.
6 Emerging Pharmacological Agents: What are
the Best Endpoints?
Due to the longnatural history of the disease, the improvement
in hard endpoints [e.g., reduction in the development of liver-
related outcomes (cirrhosis, variceal bleeds, ascites, hepato-
cellular carcinoma) and mortality] may not be feasible in a
2-year pivotal trial. Development of cirrhosis may be a suit-
able endpoint in these studies. In spite of the limitations of the
liver biopsy, there is evidence that cirrhosis on histology is
predictive of clinical outcomes. Reversal of NASH or a
decrease in disease activity (NAS) are likely to reflect a
decrease in risk of progression to cirrhosis and thus mortality.
This should be combined with either improvement or lack of
progression in the fibrosis score to ensure that true disease
reversal is captured by this endpoint. However, it is important
to note the limitations of the NAS (e.g. it has not been vali-
dated as a marker for likelihood of disease progression and/or
response to therapy and the relative impact of improvement of
steatosis vs. inflammation vs. ballooning is not clear). In any
case, it will require longterm post-approval follow-up to
demonstrate that treatment prevents cirrhosis and clinical
outcomes (e.g., progression to cirrhosis, mortality, liver-re-
lated outcomes) [61]. Additional objectives should include:
changes in cardiovascular risk profile, quality-of-life mea-
sures, assessments of healthcare resource utilization, clinical
symptoms (especially fatigue), and safety.
In early proof of concept trials, it is not practically feasible
and potentially unethical to perform multiple liver biopsies
within a short time-frame (6–24 weeks). Given these con-
siderations, the primary objectives of these early trials can be
to demonstrate proof of mechanism of action, define safety,
and gather preliminary efficacy data. A reduction in liver fat
has been consistently associated with improvement of
steatosis and inflammation. Therefore, reduction in liver fat as
assessed byMR technology can be a suitable endpoint in early
trials [35]. A composite endpoint including reduction of
hepatic steatosis and decrease in ALTmay also be considered
since this enzyme is a traditional marker of liver injury. It is
also advisable to get additional biomarkers of liver injury, e.g.,
CK-18, to add further confidence to the results [61]. Changes
in insulin sensitivity and oxidative stress, anthropometric
parameters, and changes in components of the metabolic
syndrome may provide further information about a clinically
meaningful benefit of the new compound.
The combined efforts of regulatory agencies, the phar-
maceutical industry, and academia in supporting the
development of potential therapeutic options are evident
with the several compounds with a variety of mode of
actions that are currently being tested aiming a NAFLD/
NASH indication (Table 3).
7 Available Clinical Data on Emerging
Compounds
7.1 Obeticholic Acid (OCA)
Obeticholic acid, a derivative of chenodeoxycholic acid, is
a selective Farnesoid X receptor (FXR) agonist [97]. FXR,
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a member of the nuclear receptor superfamily, is mainly
expressed in liver, intestine, kidney, and, to a lesser extent,
in adipose tissue. It regulates a variety of target genes
involved in the control of bile acids, lipid, and glucose
homeostasis, as well as genes affecting the regulation of
immune responses. FXR controls glucose metabolism
through regulation of gluconeogenesis and glycogenolysis
in the liver, and through regulation of peripheral insulin
sensitivity in skeletal muscle and adipose tissue. Treatment
with OCA has been shown to increase insulin sensitivity,
regulate glucose metabolism and lipid metabolism, and
exert anti-inflammatory properties along with marked
antifibrotic effects in preclinical models.
In a phase IIa [97] randomized, placebo-controlled,
6-week study in 23 patients with T2DM and presumed
NAFLD (high liver enzymes, enlarged liver by imaging, or
histologic diagnosis of NAFLD on prior biopsy), OCA
significantly improved insulin sensitivity (assessed as the
change post- vs. pre-treatment in the glucose infusion rate
during low- and high-dose insulin infusion periods). There
was a small but significant weight loss in the OCA relative
to the placebo arm.
The FLINT [98] trial was a randomized, placebo-con-
trolled, 72-week study in 282 subjects with confirmed
NASH and NAS C4 with at least 1 point from each com-
ponent. The primary outcome measure was a decrease in
NAS by at least 2 points without worsening of fibrosis from
baseline. A planned interim analysis of the primary out-
come showed a significant improved efficacy of OCA
(25 mg) relative to placebo and supported a decision not to
do end-of-treatment biopsies in 64 patients. A total of 50
(45 %) of 110 patients in the OCA group had improved
liver histology compared with 23 (21 %) of 109 patients in
the placebo group (p = 0.0002). More patients assigned to
OCA compared with placebo had improvement in fibrosis,
hepatocellular ballooning, steatosis, and lobular inflam-
mation. However, the proportion of patients with resolution
of NASH was not statistically higher in patients treated
with OCA compared with placebo (22 [22 %] of 102 vs. 13
[13 %] of 98; p = 0.08). Serum ALT and AST concen-
trations were significantly reduced in the OCA relative to
the placebo arm. By contrast, serum alkaline phosphatase
levels increased, and gamma glutamyl transferase (GGT)
concentrations decreased. These changes in liver enzyme
concentrations reversed after OCA was stopped. Compared
with placebo, treatment with OCA was also associated with
higher concentrations of total serum cholesterol and LDL
cholesterol, and a decrease in HDL cholesterol. Other
adverse events were generally mild to moderate in severity
and were similar in the two groups for all symptoms except
pruritus, which was reported more frequently and was more
severe in patients on OCA relative to placebo (23 vs. 6 %).
Future studies will need to provide confirmatory data about
the effects of OCA in improving markers of NAFLD as
well as its impact on liver-related outcomes. Additionally,
these studies will need to address the potential conse-
quences of lipid changes on cardiovascular outcomes.
7.2 Cysteamine Bitartrate
Cysteamine bitartrate (RP 103) is an aminothiol antioxi-
dant approved for the treatment of cystinosis. In a 24-week
pilot open-label, phase IIa clinical trial in 13 children with
biopsy-confirmed diagnosis of moderate-to-severe NAFLD
and baseline ALT and AST C2ULN, seven (64 %) sub-
jects achieved the primary objective of a reduction[50 %
from baseline values in ALT and AST levels at week 24.
There was also a significant reduction in mean ALT
(p = 0.002) and AST (p = 0.007) without a significant
change in mean BMI. No significant change in fasting
insulin levels compared with baseline were observed either
at 24 weeks or after 24 weeks of safety follow-up after
drug discontinuation, suggesting that the improvement in
ALT and AST was an insulin-independent response. Mean
CK-18 fragment levels decreased 43 % from baseline.
Following the 24-week cysteamine therapy, the mean
plasma adiponectin levels increased by 31 % compared
with the mean baseline levels. Superoxide dismutase values
increased by 25 % after the 24-week cysteamine therapy
(indicating antioxidant activity) and returned to baseline
levels at week 48 [99].
7.3 GFT505
GFT505 is dual peroxisome proliferator-activated receptor
alpha/delta (PPAR-a/d) agonist. PPARa is highly expres-
sed in the liver, where it controls genes involved in lipid
and lipoprotein metabolism. PPARd is widely expressed
and plays a critical role in mitochondrial function, fatty
acid oxidation, and insulin sensitivity in mice. In preclin-
ical models of NAFLD/NASH and liver fibrosis, GFT505
demonstrated liver-protective effects on steatosis, inflam-
mation, and fibrosis. In addition, GFT505 improved liver
dysfunction markers, decreased hepatic lipid accumulation,
and inhibited proinflammatory (interleukin-1 beta, TNFa)
and profibrotic (transforming growth factor beta, tissue
inhibitor of metalloproteinase 2, collagen type I, alpha 1,
and collagen type I, alpha 2) gene expression.
In phase II studies in abdominally obese patients with
either combined dyslipidemia or prediabetes, a 1-month
treatment with GFT505 (80 mg/day) significantly
improved lipid and glucose homeostasis. Additionally, GF-
505 treatment decreased GGT, ALT, and ALP levels [102].
A randomized, placebo-controlled, three-arm (placebo,
80 mg, and 120 mg) phase IIb (GOLDEN) trial that eval-
uated 274 subjects with biopsy-confirmed NASH and a
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NAS C3 has been completed recently. The primary out-
come of improvement in NASH without worsening of
fibrosis was not achieved. One potential explanation was
the unexpected rate of resolution of NASH in patients
randomized to placebo (NAS of 3, placebo response
rate[57 %). In the subanalysis of the population of NASH
patients with an initial NAS score of C4 (N = 120),
GFT505 at 120 mg/day led to a significant improvement on
both the primary endpoint (29 vs. 5 % for placebo;
p = 0.01) and on the lowering of the NAS score by at least
two points (48 vs. 21 % for placebo; p = 0.02). GFT505
lead to a significant reduction in LDL-cholesterol (-
9.28 mg/dL, p\ 0.001 vs. placebo) and a significant
increase in HDL-cholesterol (?4.25 mg/dL, p\ 0.01 vs.
placebo). HbA1c levels were significantly reduced in dia-
betic patients (-0.46 %, p\ 0.05 vs. placebo). The safety
assessment of this 1-year study demonstrated a favorable
safety profile. Weight remained stable, and no signal for
edema was observed. A mild dose-dependent increase in
creatinine was noted (\5 %; GFT505 120 mg vs. placebo).
The most common adverse events were of a gastrointesti-
nal nature and of mild intensity [100].
7.4 Simtuzumab
Simtuzumab is a humanized monoclonal antibody against
lysyl oxidase-like 2 (LOXL2), an enzyme that in humans is
encoded by the LOXL2 gene. It is essential to the bio-
genesis of connective tissue, encoding an extracellular
copper-dependent amine oxidase that catalyzes the first
step in the formation of cross-links in collagens and elastin,
a key component in the core regulatory pathway of
fibrogenesis.
In 20 patients with liver fibrosis of diverse etiologies,
simtuzumab (up to 10 mg/kg infused over 1 h) every
2 weeks (three infusions) appeared to be well tolerated.
The most frequently reported adverse events were
abdominal pain, fatigue, musculoskeletal pain, and head-
ache. While simtuzumab is being developed as an antifi-
brotic agent, an acute reduction in transaminases was
observed suggesting a potential anti-inflammatory effect in
addition to the antifibrotic effect [101]. A PhIIb in patients
with compensated cirrhosis secondary to NASH is cur-
rently ongoing (Table 3).
7.5 Aramchol
Aramchol is a conjugate of two natural components, cholic
acid and arachidic acid. Aramchol inhibits the activity of
stearoyl coenzyme A desaturase 1 (SCD1) in the liver. The
physiologic effects of SCD1 inhibition are: decreased
synthesis of fatty acids, resulting in a decrease in storage
triglycerides and other esters of fatty acids. This reduces
liver fat (including triglycerides and free fatty acids), and
results in an improvement in insulin resistance and anti-
atherogenic effect in animal studies. In a randomized,
double-blind, placebo-controlled trial of 60 patients with
biopsy-confirmed NAFLD (six with NASH), patients were
given aramchol (100 or 300 mg) or placebo once daily for
3 months. No serious or drug-related adverse events were
observed in the 58 patients who completed the study. Over
3 months, liver fat content decreased by 12.57–22.14 % in
patients given 300 mg/day aramchol, but increased by
6.39–36.27 % in the placebo group (p = 0 .02). Liver fat
content decreased in the 100-mg aramchol group, by
2.89–28.22 %, but this change was non-significant. [102].
There is an ongoing phase II trial in overweight/obese
patients with pre-diabetes or T2DM and NASH (Table 3).
7.6 Liraglutide
Liraglutide is a long-acting glucagon-like peptide-1
receptor agonist approved for the treatment of diabetes and,
most recently, for the treatment of obesity in adults with
related co-morbidity. A meta-analysis from six randomized
clinical trials comprised in the ‘‘Liraglutide Effect and
Action in Diabetes’’ (LEAD) program and including sev-
eral thousand patients with NAFLD [84], subjects treated
with liraglutide (1.8 mg/day for 26 weeks) showed a
reduction in ALT and hepatic steatosis at CT evaluation, as
well as in NAFLD fibrosis score. In a substudy of a ran-
domized phase II study (subgroup of NASH patients),
liraglutide (1.8 mg) significantly reduced weight, waist
circumference, HbA1c, fasting glucose, LDL, and liver
enzymes versus placebo. Liraglutide significantly reduced
circulating NEFA in the fasting state, low-dose and high-
dose insulin states, and significantly reduced adipose tissue
lipolysis. Liraglutide significantly improved serum markers
of adipose inflammation, e.g., leptin and adiponectin [103].
In the Liraglutide Efficacy and Action in NASH
(LEAN) trial overweight patients with biopsy-confirmed
NASH were randomized (1:1) to receive 48-week treat-
ment with once-daily, subcutaneous injections of either
1.8 mg liraglutide or liraglutide-placebo (control). The
primary outcome measure was improvement in liver his-
tology, defined as resolution of definite NASH and no
worsening in fibrosis. A total of nine (39 %) of 23 patients
on liraglutide had resolution of definite NASH compared to
two (9 %) of 22 patients on placebo (p = 0.019). Only two
(9 %) patients on liraglutide had worsening of fibrosis
compared to eight (36 %) on placebo (p = 0.026). As
expected, liraglutide led to weight loss (-5.3 vs. -0.6 kg,
p = 0.001) and lower fasting glucose (-1.0 vs.
-0.7 mmol, p = 0.005) compared to placebo. Reductions
in ALT (-27 vs. -10, p = 0.126) and HbA1c (-0.5 vs.
-0.03 %, p = 0.07) were also seen with liraglutide, albeit
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not significant versus placebo. Liraglutide was well toler-
ated with only two (8 %) of 26 patients withdrawing from
treatment due to drug-related gastrointestinal (nausea,
diarrhoea) side effects [104].
7.7 Emricasan
Emricasan is a potent irreversible pan-caspase inhibitor.
Caspases play a central role in the processes of apoptosis
and inflammation. They are responsible for executing
apoptotic pathways, or programmed cell death, and for
activation of cytokines such as IL-1b and IL-18. Both
caspase-mediated apoptosis and inflammation have been
shown to play important roles in the development and
progression of NASH and NAFLD, leading to the
hypothesis that inhibition of caspases may have a signifi-
cant therapeutic benefit for the treatment of NAFLD/
NASH. Emricasan reduced steatosis, inflammation, apop-
tosis, and fibrosis in preclinical models. Human studies
have demonstrated that emricasan can lower serum
transaminases after intravenous or oral administration. In a
recently completed randomized, placebo-controlled,
28-day phase II study in subjects with NAFLD and ele-
vated ALT, emricasan led to statistically significant
reductions in ALT and CK-18 (approximately 30 % rela-
tive to placebo) at day 28. Emricasan was generally well
tolerated in the study and no changes were reported in
weight, cholesterol, HDL, LDL, or triglycerides in the
study in either the emricasan or placebo arms [105].
7.8 Cenicriviroc
It is an immunomodulator and dual inhibitor of chemokine
receptors CCR2 and CCR5 (important players in the traf-
ficking ofmonocytes/macrophages and other cell types). In a
post-hoc analysis in patients with HIV, treatment with
cenicriviroc was associated with improvements in AST to
platelet ratio and FIB-4 scores, and correlations were
observed between changes in AST to platelet ratio and FIB-4
scores and sCD14 levels at week 48 [106]. There are two
ongoing phase II studies in patients with NAFLD (Table 3).
7.9 Remogliflozin
Remogliflozin is an SGLT2 inhibitor shown to reduce
HbA1c in type 2 diabetics. Remogliflozin has been shown
to improve insulin sensitivity in subjects with type 2 dia-
betes. Post-hoc analysis in a 12-week trial in diabetics
showed an approximate 40 % reduction in ALT levels in
subjects with elevated values at Baseline. Additionally,
remogliflozin has been reported to have anti-oxidant
activity as measured by the oxygen radical antioxidant
capacity (ORAC) assay and serum markers of oxidative
stress in animal models of steatohepatitis [107].
8 Strategic Considerations in Developing Drugs
to Treat Non-Alcoholic Steatohepatitis
As described above, there is much uncertainty on the
optimal endpoints to determine the efficacy of drugs in the
treatment of NASH. The hope is that with the development
of validated biomarkers, we will be able to move away
from biopsy and histopathology. There are also many
questions remaining on the natural history of NASH, and
why patients progress to this condition from NAFLD.
Fortunately, the last decade has seen regulatory agencies
implement several initiatives to expedite the development
of drugs for serious conditions such as NASH—and these
initiatives are especially applicable in cases where there is
an unmet medical need. For example, the US Food and
Drug Administration (FDA) has developed several path-
ways to expedite drug development for unmet medical
needs [108], and the European Medicines Agency (EMA)
has created similar mechanisms known collectively as
‘‘adaptive pathways’’ [109]. Often, these accelerated
development pathways to approve a drug for marketing are
referred to as conditional approvals—since they are usually
‘‘conditional’’ upon post-marketing studies. However, the
overall goal with all of the accelerated development path-
ways is to quickly bring useful drugs to patients where an
unmet medical need exists. A summary of these acceler-
ated development pathways is shown in Table 4 and a
Table 4 Examples of regulatory pathways to accelerate marketing approvals for life-saving therapies
Accelerated development pathway (location; year of introduction) Comment
Accelerated approval (USA 1992) Shortened clinical development time
Priority review (USA 1992) Shortened marketing application review time (6 months)
Fast track (USA 1997) Shortened clinical development time. Rolling review
of marketing application
Breakthrough therapy (USA 2012) Shortened clinical development time
Approval under exceptional circumstances (EU 1993) Shortened clinical development time
Conditional marketing authorization (EU 2005) Shortened clinical development time
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more in-depth discussion is provided in a recent review
[110]. These approaches are particularly relevant to NASH,
and may reduce the time to marketing approval and
reimbursement. Indeed, one company in the NASH drug
development space has already received a breakthrough
designation for an investigational compound [111]. This
designation guarantees a shortened clinical development
plan and substantial FDA engagement during the devel-
opment of the product. Consequently, it seems reasonable
to assume that regulatory agencies will be receptive to
expedited approvals for drugs to treat or prevent NASH.
Of course, pathways to accelerate drug development
cannot exist without modernizing clinical trial methodol-
ogy. A number of guidances on new clinical development
methodologies have been published by regulatory agencies
in recent years. These guidances demonstrate the need for
innovation and flexibility in developing products for con-
ditions with a major unmet medical need, such as NASH.
Examples of these clinical trial guidances include adaptive
designs [112] and enrichment strategies to support mar-
keting approvals [113]. A recent review provides additional
information on these clinical trial methodologies in greater
depth [114].
All of the above regulatory tools are likely to be
incorporated into the first successful marketing application
for the treatment of NASH. As mentioned, several com-
panies are in the process of completing phase II studies and
moving toward phase III registration studies. These com-
panies are now in discussions with regulatory agencies. A
recent industry forum on NASH suggested that surrogate
endpoints might include reversal of NASH as measured by
histologic improvement, histologic resolution, or
improvements in fibrosis; with post-approval trials looking
at clinical outcomes such as liver transplant-free survival or
progression to cirrhosis [115]. However, in the final anal-
ysis, we remain in a trial-and-error scenario with regard to
the registration pathway for a drug in the treatment of
NASH. It could be several years before we resolve the best
surrogate markers and clinical outcome endpoints.
Finally, with uncertainty in clinical endpoints and trial
design, the interaction between a wide range of stakeholders
is extremely important to explore ways to optimize devel-
opment pathways. Such stakeholders include regulatory
agencies (such as FDA and EMA), the biotech/pharmaceu-
tical industry, health-technology assessment bodies, physi-
cians, researchers, and patients. While all of these
stakeholders are important for successful drug development,
the interactions between sponsors and the regulatory agen-
cies cannot be overestimated. For example, the success rates
for drug approvals by regulatory agencies are increased
substantially when the drug developers take advantage of
meetings with regulatory agencies [116]. The quality of the
interaction between sponsor and regulatory agency will be
especially important in developing drugs for NASH—not
only to ensure selection of adequate endpoints, but to also
accelerate development using expedited pathways.
9 Conclusions and Future Directions
NAFLD is themost common cause of chronic liver disease in
the Western world today. With rising levels of obesity and
T2DM, its prevalence will increase in the future, and cause
considerable morbidity and mortality. Despite considerable
research and multiple clinical trials, at present no single
pharmacologic agent has achieved a clinically meaningful
benefit/risk profile to warrant regulatory approval for mar-
keting. The combined efforts of academia, pharmaceutical
industry, and regulatory agencies will eventually bring the
first approved therapy within a few years. The ideal drug will
need to address not only the liver complications but prevent
cardiovascular death, the main cause of mortality in this
patient population. There is a wide variety of compounds
with a different mode of actions currently in clinical devel-
opment. It is most likely that a multifaceted combination
therapy will be needed. The ideal treatment will lead, in the
short term, to a reduction in liver inflammation and fibrosis,
and an improvement in insulin sensitivity and metabolic
complications, but in the long term will need to reduce car-
diovascular and liver outcomes.
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